Pfizer Inc ((PFE)), Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pfizer Inc. and BioNTech SE have launched a clinical study titled ‘A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS.’ The study aims to assess the safety and immune response of a modified RNA vaccine for shingles in healthy adults aged 50 to 85.
The intervention involves testing a modified RNA vaccine, Varicella Zoster Virus modRNA (VZV modRNA), designed to prevent shingles by eliciting an immune response.
The study is interventional, with a randomized, sequential design. It employs a quadruple masking approach, ensuring that participants, care providers, investigators, and outcomes assessors are blinded. The primary goal is prevention.
Key dates include the actual start on January 25, 2023, with the last update submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and expected outcomes.
The study’s progress could positively impact Pfizer and BioNTech’s stock performance by showcasing their continued innovation in vaccine development. This could bolster investor confidence, especially considering the competitive landscape in the vaccine industry.
The study is ongoing, and further details are available on the ClinicalTrials portal.